CYP3

CYP3A enzymes are major cytochrome P450 monooxygenases that catalyze the oxidative metabolism of endogenous steroids, lipids, and a large proportion of clinically used xenobiotics, thereby regulating drug clearance and systemic exposure^[1][2]. Within the CYP3A subfamily, CYP3A4 is the predominant hepatic and intestinal isoform and contributes to the metabolism of approximately 30-50% of prescribed drugs, making it a central determinant of pharmacokinetic variability and drug-drug interactions^[1][3]. Mechanistically, CYP3A enzymes localize to the endoplasmic reticulum and catalyze hydroxylation, epoxidation, and dealkylation reactions that facilitate the biotransformation and elimination of structurally diverse compounds^[2][3]. Disease relevance emerges through their influence on therapeutic response, adverse drug reactions, and interindividual differences in drug disposition, particularly in the context of genetic polymorphisms affecting CYP3A activity^[1][4]. Compared with CYP3A4, CYP3A5 displays distinct tissue distribution and substrate selectivity, contributes variably to total CYP3A-mediated metabolism, and has been implicated in specific metabolic and drug-resistance phenotypes that are not fully redundant with CYP3A4 function^[2][5]. Structural and biochemical studies further demonstrate differential interactions of CYP3A4 and CYP3A5 with inhibitors, supporting isoform-selective modulation as a useful strategy for mechanistic pharmacology and experimental drug-metabolism research^[2][6].